Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Maintenance in Stage III ALK+ NSCLC
NCT07235306Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2025
- Primary completion
- Jan 2031
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07235306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235306.